Issuu on Google+

Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Report Details

• • • • • • •

Publish date: 31st Jan, 2013 Number of slides: 62 Geographic coverage: Global Available format: PDF, CD, Hardcopy Price for Single User License: USD 2,000 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal

www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Report Insights

• Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell • Tumors or cancer biology indicates that this balance is disturbed • Inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer • Resistance to existing therapies develops as cancer cells bypass these efforts and there remains an evergreen search for new targets to meet these challenges • Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Report Insights (Continued)

• Around USD 10 bn has already been invested in licensing or acquisition of PI3K and other kinase inhibitors since the last five years • Scientific data on the role of PI3K, BTK kinase in cancer, clinical Proof of Concept (PoC) data of the PI3K and BTKs inhibitors have reached a critical mass • Companies with focus in this sector are poised to offer better treatment options for unmet needs in hematologic malignancies • More acquisitions of the innovator companies and licensing deals for unpartnered products are expected, as mature data and approvals come in the next few years www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Report Coverage

• Recent progress on the understanding of PI3Ks or BTK signaling pathway • List of companies developing PI3K or BTK inhibitors (PCYC, INFI, CRIS, SymBio, GILD) • Clinical data and competition

www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Table of Contents

• • • • • • • •

Drugs in the pipeline PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD) Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS) BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG) M&A in Kinase Inhibitors in the last 5 years Related Milestones/catalysts in 2013-2014 Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers Ongoing Clinical Trials of Companies Covered

www.researchonglobalmarkets.com


Report: Drivers of M&A in 2013-2016 PI3Ks and BTK Inhibitors Table of Contents (Continued)

• Detailed reports on:  Curis (CRIS) - Time to Assess Value Beyond Erivedge!  Gilead (GILD) - New HIV + HCV Products to Sustain the Growth Trajectory  Infinity pharma (INFI) - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!  Pharmacyclics (PCYC) - Ibrutinib - Promising to Deliver More  SymBio (4582) - Significant Upside still Remains

www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com


Drivers of m&a in 2013 2016 pi3ks and btk inhibitors